U.S., April 12 -- ClinicalTrials.gov registry received information related to the study (NCT06923527) titled 'Circulating Tumor DNA: TBCRC-068' on March 27.
Brief Summary: This is a single-arm, phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
ER+ Breast Cancer
Intervention:
DRUG: Elacestrant
Administration of elacestrant will follow the FDA approved dose and schedule for patients with ER+ metastatic breast cancer. Elacestrant 345 mg will be administered orally once daily for 12 cycles or until disease progression or unaccepta...